Abstract 96P
Background
Chemotherapy combined with anti-PD-1 monoclonal antibody has already become the first-line treatment in advanced ESCC, while the benefits in objective responses and survival were limited. Cadonilimab (AK104), a bispecific antibody simultaneously targeting PD-1 and CTLA-4, was designed to boost anti-tumour activity with an improved safety profile. Here, we first evaluated the safety and efficacy of AK104 combination therapy as the first-line treatment in advanced ESCC.
Methods
Eligible pts with previously untreated unresectable locally advanced or metastatic ESCC received AK104 (10mg/kg, iv, d1, q3w) combined with paclitaxel or nab-paclitaxel (175 mg/m2, iv, d1, q3w) and cisplatin (65 to 75 mg/m2, iv, d1, q3w) for up to 6 cycles, then continued AK104 (10mg/kg, iv, d1, q3w) treatment as maintenance until progressive disease or unacceptable toxicity, with a maximum of 24 months. The primary endpoint was objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), disease control rate (DCR) and safety.
Results
As of data cut-off (September 21, 2023), 22 pts were enrolled with a median age of 61 years (range 44-75), 50.0% had PD-L1 CPS<10. In the efficacy-evaluable population (n=15), 13 pts reached partial response and 2 pts had stable disease. The ORR was 86.7% (95%CI: 58.4%-97.7%) and the DCR was 100.0% (95%CI: 74.7%-100%). Both median PFS and OS were not reached. Among evaluable pts with PD-L1 CPS≥10 and PD-L1 CPS<10, the ORR were 83.3% (5/6) and 88.9% (8/9), respectively. Seven (31.8%) pts experienced grade 3-4 TRAEs, which mainly included neutropenia (22.7%), leukopenia (9.1%) and hyponatremia (9.1%). Immune-related AEs were observed in 3pts (13.6%). 3 pts (13.6%) suffered from serious AEs, and no grade 5 TRAE was observed. AEs led to discontinuation of AK104 in 2 (9.1%) of enrolled pts.
Conclusions
Bispecific antibody AK104 combined with taxane and cisplatin showed better ORR and manageable safety as first-line treatment in advanced ESCC, regardless of PD-L1 expression. Survival outcomes will be reported in the future and single AK104 cohort in pts with PD-L1 CPS≥5 ESCC is being explored.
Clinical trial identification
NCT05522894.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
112P - Close cardiovascular monitoring during the early stages of treatment for patients receiving immune checkpoint inhibitors
Presenter: Danielle Delombaerde
Session: Poster Display
113P - A multidisciplinary management of immune-checkpoint inhibitor (ICI)-related pneumonitis to improve its clinical management
Presenter: Monica Valente
Session: Poster Display
114P - Real-World Insights on Pan-Cancer Immune Checkpoint Inhibitor Treatment: Initial Findings of a Belgian Multicenter Study
Presenter: Annelies Verbiest
Session: Poster Display
115TiP - MDT-BRIDGE: A phase 2 study of neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery and adjuvant D or chemoradiotherapy (CRT) and consolidation D in patients (pts) with resectable or borderline resectable stage IIB-IIIB NSCLC
Presenter: Martin Reck
Session: Poster Display
117TiP - BGB-HNSCC-201 (NCT05909904): Phase 2, Open-Label, Multi-Arm, Global Study of Tislelizumab (TIS) + Investigational Agents as First-Line (1L) Treatment in Patients (Pts) With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Presenter: Kevin Harrington
Session: Poster Display
121P - MK-7684A (Vibostolimab [Vibo] Plus Pembrolizumab [Pembro] Coformulation) With/Without Docetaxel in Metastatic NSCLC After Platinum-Chemotherapy (Chemo) and Immunotherapy
Presenter: Nir Peled
Session: Poster Display
123P - A phase II study of nivolumab (N) plus ipilimumab (I) and ASTX727 or N plus I in PD-1/PD-L1 resistant melanoma or NSCLC patients: the run-in phase of the NIBIT Foundation ML1 Study
Presenter: Anna Di Giacomo
Session: Poster Display
124P - Surufatinib plus toripalimab combined with etoposide (E) and cisplatin (P) in patients (pts) with advanced naive small cell lung cancer (SCLC) -Updated results of a phase ?b/? trial
Presenter: Wen Feng Fang
Session: Poster Display
126P - Evaluation of Myeloid Targeting Agents, PY159 and PY314, in Two Dose Expansion Phase 1b Trials in Platinum-Resistant Ovarian Cancer
Presenter: Oladapo Yeku
Session: Poster Display